Trillium Therapeutics Inc. (TRIL) NASDAQ
$18.44 0 (0.00%)
Market Cap: $0
As of 11/16/21 12:00 AM EST. Market closed.
Trillium Therapeutics Inc. (TRIL)
NASDAQ
$18.44
0 (0.00%)
Market Cap: $0
As of 11/16/21 12:00 AM EST. Market closed.
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune ... read more
Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system. read less
COMPANY PROFILE
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Industry
Biological Product (except Diagnostic) Manufacturing
Full Time Employees
33
Address
.
PRICE CHART FOR TRILLIUM THERAPEUTICS INC
From:
To:
NEWS
KEY STATS
Open
$18.45
Previous Close
$18.44
Days Range
$17.83 - $18.49
52 week range
$0 - $0
Volume
0
Avg. Volume (30 days)
0
Market Cap
$0
Dividend Yield
0.00%
P/E
-
Shares Outstanding
104,995,125
Open
$18.45
Previous Close
$18.44
Days Range
$17.83 - $18.49
52 week range
$0 - $0
Volume
0
Avg. Volume (30 days)
0
Market Cap
$0
Dividend Yield
0.00%
P/E
-
Shares Outstanding
104,995,125
Open in: 
Open in:
INSIDER TRANSACTIONS FOR TRILLIUM THERAPEUTICS INC
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Uger Robert | Chief Scientific Officer | Jul 07, 2021 | Option Exercise | $0.30 | 3,646 | 1,108 | 3,646 | Jul 09, 2021, 04:30 PM |
| Uger Robert | Chief Scientific Officer | Jul 07, 2021 | Sale | $9.00 | 3,646 | 32,814 | 0 | Jul 09, 2021, 04:30 PM |
| Uger Robert | Chief Scientific Officer | Apr 07, 2021 | Option Exercise | $0.30 | 3,646 | 1,098 | 3,646 | Apr 09, 2021, 05:38 PM |
| Uger Robert | Chief Scientific Officer | Apr 07, 2021 | Sale | $10.82 | 3,646 | 39,450 | 0 | Apr 09, 2021, 05:38 PM |
| Petrova Penka | Chief Development Officer | Apr 08, 2021 | Option Exercise | $1.80 | 5,312 | 9,578 | 5,312 | Apr 09, 2021, 05:23 PM |
| Petrova Penka | Chief Development Officer | Apr 08, 2021 | Sale | $11.09 | 5,312 | 58,910 | 0 | Apr 09, 2021, 05:23 PM |
| Uger Robert | Chief Scientific Officer | Mar 12, 2021 | Option Exercise | $3.39 | 2,917 | 9,896 | 2,917 | Mar 15, 2021, 05:12 PM |
| Uger Robert | Chief Scientific Officer | Mar 12, 2021 | Sale | $11.97 | 2,917 | 34,916 | 0 | Mar 15, 2021, 05:12 PM |
| Petrova Penka | Chief Development Officer | Mar 10, 2021 | Option Exercise | $1.80 | 5,312 | 9,545 | 5,312 | Mar 12, 2021, 04:40 PM |
| Petrova Penka | Chief Development Officer | Mar 10, 2021 | Sale | $11.08 | 5,312 | 58,857 | 0 | Mar 12, 2021, 04:40 PM |
| Uger Robert | Chief Scientific Officer | Mar 08, 2021 | Option Exercise | $0.30 | 3,646 | 1,093 | 3,646 | Mar 10, 2021, 05:57 PM |
| Uger Robert | Chief Scientific Officer | Mar 08, 2021 | Sale | $10.11 | 3,646 | 36,861 | 0 | Mar 10, 2021, 05:57 PM |
| Petrova Penka | Chief Development Officer | Feb 09, 2021 | Option Exercise | $9.62 | 508 | 4,888 | 508 | Feb 10, 2021, 07:18 PM |
| Petrova Penka | Chief Development Officer | Feb 08, 2021 | Option Exercise | $1.78 | 5,312 | 9,435 | 5,312 | Feb 10, 2021, 07:18 PM |
| Petrova Penka | Chief Development Officer | Feb 08, 2021 | Sale | $12.65 | 5,312 | 67,197 | 0 | Feb 10, 2021, 07:18 PM |
| Petrova Penka | Chief Development Officer | Feb 09, 2021 | Sale | $14.17 | 508 | 7,200 | 0 | Feb 10, 2021, 07:18 PM |
| Uger Robert | Chief Scientific Officer | Feb 09, 2021 | Option Exercise | $9.62 | 584 | 5,619 | 584 | Feb 10, 2021, 07:18 PM |
| Uger Robert | Chief Scientific Officer | Feb 08, 2021 | Option Exercise | $1.64 | 6,563 | 10,751 | 6,563 | Feb 10, 2021, 07:18 PM |
| Uger Robert | Chief Scientific Officer | Feb 09, 2021 | Sale | $14.12 | 584 | 8,248 | 0 | Feb 10, 2021, 07:18 PM |
| Uger Robert | Chief Scientific Officer | Feb 08, 2021 | Sale | $12.65 | 6,563 | 83,022 | 0 | Feb 10, 2021, 07:18 PM |
| Skvarka Jan | President and CEO | Jan 13, 2021 | Option Exercise | $0.42 | 5,419 | 2,302 | 5,419 | Jan 15, 2021, 04:19 PM |
| Skvarka Jan | President and CEO | Jan 14, 2021 | Option Exercise | $0.43 | 19,581 | 8,371 | 19,581 | Jan 15, 2021, 04:19 PM |
| Skvarka Jan | President and CEO | Jan 14, 2021 | Sale | $15.03 | 19,581 | 294,279 | 0 | Jan 15, 2021, 04:19 PM |
| Skvarka Jan | President and CEO | Jan 13, 2021 | Sale | $15.04 | 5,419 | 81,508 | 0 | Jan 15, 2021, 04:19 PM |
| Uger Robert | Chief Scientific Officer | Jan 11, 2021 | Option Exercise | $9.57 | 584 | 5,587 | 584 | Jan 13, 2021, 04:12 PM |
| Uger Robert | Chief Scientific Officer | Jan 11, 2021 | Sale | $15.20 | 584 | 8,879 | 0 | Jan 13, 2021, 04:12 PM |
| Petrova Penka | Chief Development Officer | Jan 11, 2021 | Option Exercise | $9.57 | 508 | 4,860 | 508 | Jan 13, 2021, 04:11 PM |
| Petrova Penka | Chief Development Officer | Jan 11, 2021 | Sale | $15.21 | 508 | 7,725 | 0 | Jan 13, 2021, 04:11 PM |
| Parsons James T. | Chief Financial Officer | Jan 08, 2021 | Option Exercise | $7.24 | 8,505 | 61,616 | 8,505 | Jan 12, 2021, 04:12 PM |
| Parsons James T. | Chief Financial Officer | Jan 08, 2021 | Sale | $15.79 | 8,505 | 134,271 | 0 | Jan 12, 2021, 04:12 PM |
| Uger Robert | Chief Scientific Officer | Jan 08, 2021 | Option Exercise | $8.38 | 8,517 | 71,365 | 5,600 | Jan 12, 2021, 04:11 PM |
| Uger Robert | Chief Scientific Officer | Jan 08, 2021 | Sale | $15.71 | 8,517 | 133,806 | 0 | Jan 12, 2021, 04:11 PM |
| Petrova Penka | Chief Development Officer | Jan 08, 2021 | Option Exercise | $3.33 | 2,604 | 8,674 | 2,604 | Jan 12, 2021, 04:10 PM |
| Petrova Penka | Chief Development Officer | Jan 08, 2021 | Sale | $15.50 | 2,604 | 40,365 | 0 | Jan 12, 2021, 04:10 PM |
| Petrova Penka | Chief Development Officer | Jan 07, 2021 | Option Exercise | $0.30 | 2,708 | 809 | 2,708 | Jan 11, 2021, 04:19 PM |
| Petrova Penka | Chief Development Officer | Jan 07, 2021 | Sale | $14.71 | 2,708 | 39,843 | 0 | Jan 11, 2021, 04:19 PM |
| Uger Robert | Chief Scientific Officer | Jan 07, 2021 | Option Exercise | $0.30 | 3,646 | 1,089 | 3,646 | Jan 11, 2021, 04:17 PM |
| Uger Robert | Chief Scientific Officer | Jan 07, 2021 | Sale | $14.75 | 3,646 | 53,782 | 0 | Jan 11, 2021, 04:17 PM |
Load More Insider Transactions
Buy
Sale
Option Exercise
| Owner | Relationship | Date | Value($) |
| Uger Robert | Chief Scientific Officer | 07/07/2021 | 1,108 |
| Uger Robert | Chief Scientific Officer | 07/07/2021 | 32,814 |
| Uger Robert | Chief Scientific Officer | 04/07/2021 | 1,098 |
| Uger Robert | Chief Scientific Officer | 04/07/2021 | 39,450 |
| Petrova Penka | Chief Development Officer | 04/08/2021 | 9,578 |
| Petrova Penka | Chief Development Officer | 04/08/2021 | 58,910 |
| Uger Robert | Chief Scientific Officer | 03/12/2021 | 9,896 |
| Uger Robert | Chief Scientific Officer | 03/12/2021 | 34,916 |
| Petrova Penka | Chief Development Officer | 03/10/2021 | 9,545 |
| Petrova Penka | Chief Development Officer | 03/10/2021 | 58,857 |
| Uger Robert | Chief Scientific Officer | 03/08/2021 | 1,093 |
| Uger Robert | Chief Scientific Officer | 03/08/2021 | 36,861 |
| Petrova Penka | Chief Development Officer | 02/09/2021 | 4,888 |
| Petrova Penka | Chief Development Officer | 02/08/2021 | 9,435 |
| Petrova Penka | Chief Development Officer | 02/08/2021 | 67,197 |
| Petrova Penka | Chief Development Officer | 02/09/2021 | 7,200 |
| Uger Robert | Chief Scientific Officer | 02/09/2021 | 5,619 |
| Uger Robert | Chief Scientific Officer | 02/08/2021 | 10,751 |
| Uger Robert | Chief Scientific Officer | 02/09/2021 | 8,248 |
| Uger Robert | Chief Scientific Officer | 02/08/2021 | 83,022 |
| Skvarka Jan | President and CEO | 01/13/2021 | 2,302 |
| Skvarka Jan | President and CEO | 01/14/2021 | 8,371 |
| Skvarka Jan | President and CEO | 01/14/2021 | 294,279 |
| Skvarka Jan | President and CEO | 01/13/2021 | 81,508 |
| Uger Robert | Chief Scientific Officer | 01/11/2021 | 5,587 |
| Uger Robert | Chief Scientific Officer | 01/11/2021 | 8,879 |
| Petrova Penka | Chief Development Officer | 01/11/2021 | 4,860 |
| Petrova Penka | Chief Development Officer | 01/11/2021 | 7,725 |
| Parsons James T. | Chief Financial Officer | 01/08/2021 | 61,616 |
| Parsons James T. | Chief Financial Officer | 01/08/2021 | 134,271 |
| Uger Robert | Chief Scientific Officer | 01/08/2021 | 71,365 |
| Uger Robert | Chief Scientific Officer | 01/08/2021 | 133,806 |
| Petrova Penka | Chief Development Officer | 01/08/2021 | 8,674 |
| Petrova Penka | Chief Development Officer | 01/08/2021 | 40,365 |
| Petrova Penka | Chief Development Officer | 01/07/2021 | 809 |
| Petrova Penka | Chief Development Officer | 01/07/2021 | 39,843 |
| Uger Robert | Chief Scientific Officer | 01/07/2021 | 1,089 |
| Uger Robert | Chief Scientific Officer | 01/07/2021 | 53,782 |
Load More Insider Transactions
CHANGE IN SHARES OUTSTANDING FOR TRILLIUM THERAPEUTICS INC
STOCK BUYBACKS FOR TRILLIUM THERAPEUTICS INC
Period of Report: 09/30/2021
10-K/10-Q Filings: View
Previous Period
% Change in Shares
Quarter
06/30/2021
0.48%
1Q
03/31/2021
0.86%
2Q
12/31/2020
22.80%
3Q